
Xolair Coupons & Savings Card – Discount Prices from $3214.47
My prescription
Edit
2ML of 300MG/2ML, Xolair (1 Syringe)
Select pharmacy

Albertsons
$3214.47
COUPON PRICE
Walgreens
$3220.07
COUPON PRICE
Walmart
$3233.12
COUPON PRICEXolair savings card
Show this card to your pharmacist
Albertsons
$3214.47
BIN
ID
PCN
GRP
019876
LHB65E5A5A
CHIPPO
LHX
Powered by
More prescriptions for asthma
More prescriptions for asthma
Price history for Xolair
1 Syringe, 2ML of 300MG/2ML
Average retail price for Xolair
Average SaveHealth price for Xolair
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Xolair dosage forms
Dosage Quantity Price from Per unit 0.5ML of 75MG/0.5ML 1 Syringe $804.50 $804.50 0.5ML of 75MG/0.5ML 2 Syringes $1609.24 $804.62 0.5ML of 75MG/0.5ML 3 Syringes $2412.73 $804.24 1ML of 150MG/ML 1 Syringe $1609.23 $1609.23 1ML of 150MG/ML 2 Syringes $3214.46 $1607.23 1ML of 150MG/ML 3 Syringes $4817.94 $1605.98 2ML of 300MG/2ML 1 Syringe $3214.47 $3214.47 2ML of 300MG/2ML 2 Syringes $6421.45 $3210.72 2ML of 300MG/2ML 3 Syringes $9628.42 $3209.47
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 0.5ML of 75MG/0.5ML | 1 Syringe | $804.50 | $804.50 |
| 0.5ML of 75MG/0.5ML | 2 Syringes | $1609.24 | $804.62 |
| 0.5ML of 75MG/0.5ML | 3 Syringes | $2412.73 | $804.24 |
| 1ML of 150MG/ML | 1 Syringe | $1609.23 | $1609.23 |
| 1ML of 150MG/ML | 2 Syringes | $3214.46 | $1607.23 |
| 1ML of 150MG/ML | 3 Syringes | $4817.94 | $1605.98 |
| 2ML of 300MG/2ML | 1 Syringe | $3214.47 | $3214.47 |
| 2ML of 300MG/2ML | 2 Syringes | $6421.45 | $3210.72 |
| 2ML of 300MG/2ML | 3 Syringes | $9628.42 | $3209.47 |
What exactly does XOLAIR do?
XOLAIR (omalizumab) is a medication used to treat moderate to severe persistent asthma in patients who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. It is also used for chronic idiopathic urticaria in patients who remain symptomatic despite antihistamine treatment. XOLAIR works by binding to immunoglobulin E (IgE), which plays a key role in allergic reactions, thereby reducing the amount of IgE available to trigger allergic responses.
Can XOLAIR prevent anaphylaxis?
XOLAIR (omalizumab) is not specifically approved for the prevention of anaphylaxis. It is primarily used to treat moderate to severe persistent asthma and chronic idiopathic urticaria. While it may have some effect on reducing allergic reactions, it should not be relied upon as a preventive measure for anaphylaxis. Patients at risk for anaphylaxis should continue to carry and use an epinephrine auto-injector as prescribed by their healthcare provider.
Who is a candidate for XOLAIR?
Candidates for XOLAIR (omalizumab) typically include individuals with moderate to severe persistent asthma who are 6 years of age or older and have a positive skin test or in vitro reactivity to a perennial aeroallergen. It is also used for patients with chronic idiopathic urticaria who are 12 years of age or older and remain symptomatic despite antihistamine treatment. A healthcare provider will evaluate the patient's specific condition, medical history, and other factors to determine if XOLAIR is appropriate.
Does XOLAIR cure urticaria?
XOLAIR (omalizumab) does not cure urticaria, but it can help manage and reduce the symptoms of chronic spontaneous urticaria in patients who do not respond adequately to antihistamines. It works by targeting and reducing the activity of IgE, an antibody involved in allergic reactions. Treatment with XOLAIR can lead to a significant reduction in hives and itching, improving the quality of life for patients. However, it is important for patients to continue regular consultations with their healthcare provider to monitor their condition and adjust treatment as necessary.
What is the success rate of Xolair for hives?
Xolair (omalizumab) has been shown to be effective in treating chronic spontaneous urticaria (hives) in patients who do not respond to antihistamines. Clinical studies have demonstrated that a significant number of patients experience a reduction in hives and itchiness. While individual responses can vary, many patients report a noticeable improvement in symptoms. It is important for patients to discuss their specific condition and treatment expectations with their healthcare provider.
